Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

4,016 public trials 394 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

NCT01336608

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Newport Beach, California, United States
  • GSK Investigational Site Torrance, California, United States
View all 72 locations
View Trial Details
Completed

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01372410

Conditions
Bronchial Diseases, Bronchitis, Bronchitis, Chronic, +11 more
Locations
  • GSK Investigational Site Costa Mesa, California, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Duluth, Georgia, United States
  • GSK Investigational Site Edina, Minnesota, United States
View all 13 locations
View Trial Details
Completed

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

NCT01124422

Conditions
Chronic Disease, Disease Attributes, Dyspnea, +9 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Torrance, California, United States
  • GSK Investigational Site Fort Collins, Colorado, United States
View all 27 locations
View Trial Details
Completed

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

NCT01110200

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Florence, Alabama, United States
  • GSK Investigational Site Mobile, Alabama, United States
View all 103 locations
View Trial Details
Completed

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

NCT00950807

Conditions
Bronchial Diseases, Bronchitis, Bronchitis, Chronic, +11 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site San Diego, California, United States
  • GSK Investigational Site Upland, California, United States
  • GSK Investigational Site Cincinnati, Ohio, United States
View all 19 locations
View Trial Details
Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

NCT01039675

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Chester, South Carolina, United States
  • GSK Investigational Site Gaffney, South Carolina, United States
  • GSK Investigational Site Greenville, South Carolina, United States
  • GSK Investigational Site Greenwood, South Carolina, United States
View Trial Details
Completed

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

NCT02157935

Conditions
COPD Patients, Chronic Disease, Disease Attributes, +6 more
Locations
  • Research Site Andalusia, Alabama, United States
  • Research Site Andalusia, Alabama, United States
  • Research Site Birmingham, Alabama, United States
  • Research Site Birmingham, Alabama, United States
View all 371 locations
View Trial Details

Related conditions